[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,464,737
  • Shares Outstanding, K 107,352
  • Annual Sales, $ 761,410 K
  • Annual Income, $ 99,650 K
  • EBIT $ -8 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.36
  • Price/Sales 8.42
  • Price/Cash Flow 66.12
  • Price/Book 10.04

Options Overview Details

View History
  • Implied Volatility 45.00% (-4.96%)
  • Historical Volatility 51.43%
  • IV Percentile 12%
  • IV Rank 8.10%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 24) 4.89 (8.12%)
  • Put/Call Vol Ratio 1.10
  • Today's Volume 362
  • Volume Avg (30-Day) 1,151
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 19,369
  • Open Int (30-Day) 25,768
  • Expected Range 55.33 to 65.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 3
  • High Estimate $0.02
  • Low Estimate $-0.09
  • Prior Year $0.29
  • Growth Rate Est. (year over year) -113.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.24 +36.12%
on 04/23/26
60.95 -1.20%
on 05/22/26
+13.65 (+29.31%)
since 04/22/26
3-Month
31.81 +89.31%
on 03/13/26
60.95 -1.20%
on 05/22/26
+25.40 (+72.95%)
since 02/20/26
52-Week
28.66 +110.12%
on 02/19/26
91.00 -33.82%
on 10/08/25
-15.87 (-20.86%)
since 05/22/25

Most Recent Stories

More News
S&P 500 and Nasdaq 100 Post New Record Highs on Chip Stock Strength

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.58%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.04%. June E-mini...

GOOGL : 382.97 (-1.21%)
AAPL : 308.82 (+1.26%)
INTU : 319.94 (+4.19%)
ADI : 397.07 (+3.35%)
F : 14.93 (+9.22%)
WIX : 53.19 (-3.71%)
AKAM : 147.23 (+0.68%)
TXN : 309.21 (+3.63%)
$IUXX : 29,481.64 (+0.42%)
ASML : 1,632.90 (+2.57%)
ZNM26 : 109-310 (+0.66%)
MSFT : 418.57 (-0.12%)
Chip Stock Strength Lifts the Broader Market

The S&P 500 Index ($SPX ) (SPY ) today is up +0.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. June E-mini S&P futures (ESM26...

ADI : 397.07 (+3.35%)
WIX : 53.19 (-3.71%)
AKAM : 147.23 (+0.68%)
TXN : 309.21 (+3.63%)
$IUXX : 29,481.64 (+0.42%)
ZNM26 : 109-310 (+0.66%)
DT : 41.21 (+5.26%)
ESM26 : 7,559.25 (+0.91%)
QCOM : 238.16 (+11.60%)
$DOWI : 50,579.70 (+0.58%)
SPY : 745.64 (+0.39%)
DIA : 506.12 (+0.60%)
Stocks Pressured by Signs of Resurgent Inflation

The S&P 500 Index ($SPX ) (SPY ) today is down -0.19%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.05%. June E-mini S&P futures (ESM26...

ADI : 397.07 (+3.35%)
WIX : 53.19 (-3.71%)
AKAM : 147.23 (+0.68%)
$IUXX : 29,481.64 (+0.42%)
ZNM26 : 109-310 (+0.66%)
DT : 41.21 (+5.26%)
ESM26 : 7,559.25 (+0.91%)
LRCX : 305.35 (+1.03%)
$DOWI : 50,579.70 (+0.58%)
SPY : 745.64 (+0.39%)
DIA : 506.12 (+0.60%)
ON : 116.20 (+6.01%)
3 Reasons to Sell CORT and 1 Stock to Buy Instead

3 Reasons to Sell CORT and 1 Stock to Buy Instead

CORT : 60.22 (+0.89%)
3 High-Flying Stocks We Think Twice About

3 High-Flying Stocks We Think Twice About

CORT : 60.22 (+0.89%)
HIMX : 21.04 (+5.78%)
WMT : 120.27 (-0.88%)
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

CORT : 60.22 (+0.89%)
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates

Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates

CORT : 60.22 (+0.89%)
Corcept: Q1 Earnings Snapshot

Corcept: Q1 Earnings Snapshot

CORT : 60.22 (+0.89%)
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Revenue of $164.9 million, compared to $157.2 million in first quarter 2025 Increase in 2026 revenue guidance to $950 – $1,050 million ...

CORT : 60.22 (+0.89%)
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: < 0.0001)

CORT : 60.22 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 62.34
2nd Resistance Point 61.65
1st Resistance Point 60.93
Last Price 60.22
1st Support Level 59.52
2nd Support Level 58.83
3rd Support Level 58.11

See More

52-Week High 91.00
Fibonacci 61.8% 67.19
Last Price 60.22
Fibonacci 50% 59.83
Fibonacci 38.2% 52.47
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.